Myeloma Novel Drug Targets and agents
Alternative Splicing and Non-Homologous End Joining Pathways Are Vulnerabilities Associated With Loss of The Tumor Suppressor TENT5C in Myeloma
Oumaima Jaouadi, Ph.D
Postdoctoral Fellow in Medicine
Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States